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Integrin cytoplasmic domain-associated protein 1 (ICAP-1) has been shown to interact specifically with the 1 integrin
cytoplasmic domain and to control cell spreading on fibronectin. Interestingly, ICAP-1 also is observed in the nucleus, by
immunocytochemical staining, and after biochemical cell fractionation, suggesting that it has additional roles that have
yet to be determined. We show that the nucleocytoplasmic shuttling capability of ICAP-1 is dependent on a functional
nuclear localization signal. In addition, overexpression of 1 integrin strongly reduced this nuclear localization, suggest-
ing that integrin activity could modulate ICAP-1 shuttling by sequestering it in the cytoplasm. Indeed, the nuclear
localization of ICAP-1 is dependent on the stage of cell spreading on fibronectin, and we also show that ICAP-1 expression
stimulates cellular proliferation in a fibronectin-dependent manner. This function is dependent on its nuclear localization.
Moreover, ICAP-1 is able to activate the c-myc promoter in vitro. Together, these results demonstrate that ICAP-1 shuttles
between the nucleus and cytoplasm in a 1 integrin-dependent manner. It could act as a messenger that relays information
from sites of integrin-dependent cell adhesion to the nucleus for controlling gene expression and cell proliferation.
INTRODUCTION
Integrin adhesion receptors transduce signals that control
complex cell functions such as proliferation, differentiation,
and survival, which require the regulation of gene expres-
sion. Integrins are major extracellular matrix receptors and
connect to the actin cytoskeleton through the assembly of
specialized sites known as focal complexes and focal adhe-
sions (Kaverina et al., 2002). Integrin-mediated cell adhesion
initiates dramatic cytoskeletal rearrangements and signal
transduction processes. The intracellular domain of inte-
grins has no catalytic function, indicating that its interaction
with other transducing molecules is crucial for signaling.
Recent data have suggested that adhesion receptors and
their cytosolic partners can regulate the trafficking of signal-
ing proteins between the cytoplasm and nucleus where they
control transcription. One of the best described examples of
such a phenomenon is the functional connection between
lymphocyte function-associated antigen 1 (LFA-1, a 2 inte-
grin family member), and Jun activation domain binding
protein 1 (JAB-1). A two-hybrid screen identified JAB-1 as a
protein that binds to the 2 integrin cytoplasmic tail (Bianchi
et al., 2000). JAB-1 is also a known coactivator of the c-Jun
transcription factor and localizes both in the nucleus and at
the plasma membrane. LFA-1 engagement is accompanied
by an increase in the nuclear pool of JAB-1 and the subse-
quent enhancement of activator protein-1–driven promoter
activities. Another protein, Hic-5, a paxillin-related focal
adhesion protein, can interact with the glucocorticoid recep-
tor transactivation domain and acts as a coactivator of this
transcription factor (Thomas et al., 1999; Yang et al., 2000). In
a further example involving nonintegrin surface adhesion
receptors, CASK/LIN-2, a member of the membrane-associ-
ated guanylate kinase family, shuttles between synapses
where it binds the transmembrane proteins neurexin and
syndecan, and the nucleus interacting with the Tbr-1 tran-
scription factor. The localization of CASK is dependent on
the relative levels of these cytoplasmic and nuclear anchors.
High levels of Tbr-1 recruit CASK to the nucleus and trigger
gene transcription, including that of reelin required for ce-
rebrocortical development (Hsueh et al., 2000). In contrast, a
high level of syndecan 3, which acts as the transmembrane
anchor, increases the CASK cytoplasmic pool. Similarly,
other reports have established direct linkages between tran-
scriptional regulators and cell adhesion molecules at cell-cell
junctions. The most compelling evidence for adhesion-asso-
ciated molecules involved in the regulation of transcription
comes from studies on -catenin. This protein is able to
interact with E-cadherin at cell-cell contacts, with the adeno-
matous polyposis coli and axin complex in the cytoplasm,
and with lymphocyte-enhancer binding factor 1/T-cell fac-
tor in nucleus (Ben-Ze’ev et al., 2000). The membrane-asso-
ciated guanylate kinase homologue zonula occludens-1 also
moves between cell-cell contacts where it binds -catenin
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and the nucleus in a cell density-dependent manner (Ben-
Ze’ev et al., 2000). In this way, it might impact on epithelial
differentiation and morphogenesis by interacting with Y-box
transcription factor and by regulating the expression of erb-2
(Balda and Matter, 2000). Further examples are zyxin, li-
poma preferred partner, thyroid receptor interacting pro-
tein-6, FHL-2, Ajuba, and p120, all of which are predomi-
nantly localized in focal adhesions or cell-cell contacts but
additionally shuttle to the nucleus (Wang et al., 1999; Ka-
nungo et al., 2000; Muller et al., 2000; Nix et al., 2001; Morlon
and Sassone-Corsi, 2003; Petit et al., 2003; Roczniak-Fergu-
son and Reynolds, 2003).
Among cytoplasmic proteins interacting with the intracel-
lular tails of integrins, the integrin cytoplasmic domain-
associated protein 1 (ICAP-1) has been shown to interact
specifically with the 1 integrin chain (Chang et al., 1997).
ICAP-1 is a 200-amino acid protein containing a phospho-
tyrosine binding (PTB) domain that interacts with the cyto-
plasmic tail of the 1 integrin at a NPXY motif (Chang et al.,
2002). Similarly, ICAP-1 recognizes an NPXY amino acid
sequence within KRIT-1, a protein involved in the human
disease, cerebral cavernous malformation 1 (Zhang et al.,
2001; Gunel et al., 2002; Zawistowski et al., 2002). Previous
data have suggested that phosphorylation of ICAP-1 on
threonine 38 by CaMKII modulates 51 integrin function
(Bouvard and Block, 1998). A further involvement of ICAP-1
in the regulation of 1 integrin function was suggested by
experiments indicating that its overexpression increases 1-
dependent cell motility on adhesion substrates such as fi-
bronectin (Zhang and Hemler, 1999). Talin and ICAP-1 com-
pete for binding on the cytosolic domain of the 1 integrin
chain and high concentrations of ICAP-1 disrupt focal ad-
hesions (Bouvard et al., 2003). The identification of the Rho
family GTPases Cdc42 and Rac1 as binding partners for
ICAP-1 (Degani et al., 2002) suggests an implication of
ICAP-1 in integrin-dependent signaling pathways. Addi-
tionally, we showed recently that ICAP-1 interacts with
Nm23-H2 (also called NDPK-B), a protein with nucleoside
diphosphate kinase activity (Fournier et al., 2002). Nm23-H2
is linked to a variety of cellular activities, including the
suppression of metastasis and activation of c-myc transcrip-
tion (Postel et al., 1993; Berberich and Postel, 1995). ICAP-1
and Nm23-H2 colocalize in ruffles upon integrin ligation
(Fournier et al., 2002). Very little is known, however, about
the biological functions of ICAP-1. Interestingly, ICAP-1 was
often observed both in the nucleus and cytosol. Because the
distribution pattern of a protein within the cell provides
important clues to its function, we used a combination of
immunofluorescence microscopy and biochemical fraction-
ation to determine the subcellular localization of ICAP-1 in
epithelial and fibroblastic cells. Our results show that
ICAP-1 has a functional nuclear localization signal (NLS)
sequence and belongs to the growing family of nucleocyto-
plasmic shuttles. We also report a physiological relevance of
this shuttling: ICAP-1 nuclear localization is dependent on
the stage of cell spreading on fibronectin and is clearly
related to an increase in cell proliferation, possibly through
the activation of the c-myc promoter.
MATERIALS AND METHODS
Reagents
Fibronectin was extracted from human plasma according to the method
described previously (Engvall and Ruoslahti, 1977). Monoclonal antibodies
against Nm23-H1 were purchased from Seigakaku America (Rockville, MD),
anti-lamin B antibody was from Santa Cruz Biotechnology (Santa Cruz, CA),
and anti-actin polyclonal antibodies were from Sigma-Aldrich (St. Louis,
MO). Rhodamin-phalloidin was from Sigma-Aldrich. Rabbit anti-ICAP-1 se-
rum was raised in our laboratory by immunizing rabbits with purified re-
combinant ICAP-1 protein, and mouse monoclonal antibody (mAb) anti-
ICAP-1 4D1D6 was prepared using recombinant His-tagged ICAP-1 as
antigen, as described previously (Bouvard et al., 2003). The mAb 4B7R,
directed against human 1 integrin, was purchased from NeoMarkers (Fre-
mont, CA). Anti-bromodeoxyuridine (BrdU) mAb was from Sigma-Aldrich.
Anti-cyclin D1 mAb was from Santa Cruz Biotechnology. Goat anti-mouse
IgG and goat anti-rabbit IgG coupled to horseradish peroxidase were from
Bio-Rad (Hercules, CA) and Jackson ImmunoResearch Laboratories (West
Grove, PA), respectively.
Expression Plasmid Construction
Full-length human ICAP-1 was excised from the pBS-ICAP-1 vector as an
EcoRI/XbaI fragment and inserted into the pcDNA3.1() vector (Invitrogen,
Breda, The Netherlands). The 1- to 99-nt cDNA fragment corresponding to the
N terminus of ICAP-1 was cut from pet19b/1–99 ICAP-1 by digestion with
BglII and BamHI enzymes before cloning into pcDNA3.1 already cut with
BamHI. The 100- to 200-nt C-terminal fragment of ICAP-1 was generated by
polymerase chain reaction (PCR), allowing to generate a 5Kpn end and a
3Xho end to introduce the fragment into the KpnI/XhoI sites of pcDNA3.1.
The site-directed mutagenesis for the NLS functional analysis was carried out
on pcDNA3.1/ICAP-1 with the QuikChange site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene, La Jolla, CA). The
two lysines at position 6–7 were changed to alanines. This vector was called
pcDNA3.1/ICAP-1NLS. The human ICAP-1 cDNA fragment was excised
from the pcDNA3.1/ICAP-1 vector with BamHI and HincII enzymes and
inserted into the pTREhyg vector (BD Biosciences Clontech, Palo Alto, CA)
digested with BamHI and EcoRV. The pTREhyg/ICAP-1NLS was generated
by mutagenesis by using the same strategy. All sequences were verified by
DNA sequencing. The plasmid pcmyc-NHE was kindly provided by E. Postel
(Lewis Thomas Laboratory, Princeton, NJ) and the pcDNA3.1/-actinin vec-
tor was a generous gift from A. Duperray (Institut Albert Bonniot, Grenoble,
France). The pcDNA3/Nm23-H2 was generously provided by M. L. Lacombe
(Faculte´ de Medecine Saint Antoine, Paris, France). The pECE human 1
integrin was kindly provided by E. Ruoslahti (The Burnham Institute,
La Jolla, CA).
Cell Culture and Cell Transfection
Chinese hamster ovary (CHO), HeLa, and GD25 cell lines were cultured in
-minimal essential medium (MEM) supplemented with 10% calf serum and
penicillin/streptomycin at 37°C in 5% CO2-humidified chamber. The human
lung cell line H358 was grown in RPMI 1640 medium supplemented with 10%
calf serum and penicillin/streptomycin. Cells were transiently transfected
with the cDNA constructs, by using Exgen 500 (Euromedex, Mundolsheim,
France) and the expression of the transgene was assessed between 24 and 48 h
after transfection. Transfection of H358/tet-on or Madin-Darby canine kidney
(MDCK)/tet-off epithelial cells was carried out with the use of FuGene (Roche
Diagnostics, Indianapolis, IN) and Lipofectamine, respectively. To select sta-
ble clones after transfection, H358 or MDCK cells were cultured in medium
containing either Geneticin (G418) and hygromycin, or puromycin and hy-
gromycin.
A targeted deletion of ICAP-1 was generated by homologous recombina-
tion in embryonic stem cells and introduced in mice. The generation and
characterization of the ICAP-1 knockout mice will be reported in a separate
article. Primary osteoblasts were isolated from wild-type mice and mice that
were homozygous null for ICAP-1 by using standard procedure (Globus et al.,
1998). Osteoblasts were cultured in -MEM with 10% calf serum and peni-
cillin/streptomycin. Primary cells were then immortalized using the large T
antigen by retroviral infection. Among several clones, SV2.1 and SV6.5 de-
rived from ICAP-1 null mouse and wild-type mouse, respectively, were used
in this study. ICAP-1 and EGFP cDNA were inserted as a bicistronic element
into pCL-MFG retroviral vector (Naviaux et al., 1996). Retroviral supernatant
was produced by transient transfection of phoenix cells and used to infect
SV2.1 and SV6.5 cells. Infection was confirmed by fluorescence-activated cell
sorting (FACS) analysis for enhanced green fluorescent protein (EGFP) fluo-
rescence, and cell sorting was performed to obtain a homogeneous popula-
tion.
Protein Immunoblot Analysis
CHO cells were transiently transfected with Exgen 500 (Euromedex). Twenty-
four hours after the transfection, the cells were lysed in radioimmunoprecipi-
tation assay (RIPA) buffer containing proteases and phosphatases inhibitors
for 45 min, and proteins were subjected to electrophoresis and transferred to
polyvinylidene diflouride (PVDF) membranes. The samples were analyzed by
Western blot with either rabbit polyclonal or mouse monoclonal anti-ICAP-1
antibodies, and with anti-actin, anti-Nm23-H1, and anti-lamin C antibodies.
Immunological detection was achieved with horseradish peroxidase-conju-
gated secondary antibody (Bio-Rad or Jackson ImmunoResearch Laborato-
ries), and the detection was carried out with enhanced chemiluminescence
(ECL) according to the manufacturer’s instructions (Amersham Biosciences,
Piscataway, NJ).
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Immunofluorescence Staining of Cells
CHO, GD25, and MDCK cells were cultured as a monolayer in DMEM
medium containing 10% fetal calf serum (FCS) and harvested with trypsin/
EDTA. The cells were plated on coverslips that were precoated with 10 g/ml
human plasma fibronectin in a 37°C incubator with 5% CO2 to reach 50%
confluence the day of transfection. The cells were fixed with 3% paraformal-
dehyde in phosphate-buffered saline (PBS), permeabilized with 0.2% Triton
X-100 in PBS. Nonspecific sites were blocked in 10% goat serum for 1 h at
room temperature. Cells were stained for 1 h with either monoclonal or
polyclonal antibodies in a moist chamber. Anti ICAP-1 4D1D6 monoclonal
antibodies issued from hybridoma supernatant was used at 1:3 and anti-
ICAP-1 polyclonal antibodies were used at 1:1000. The 4B7R mAb specific for
human 1 integrin was used at 1:200. After rinsing, coverslips were incubated
with an appropriate Alexa-conjugated secondary antibody (Molecular Probes,
Eugene, OR) for 30 min. The cells were mounted in Mowiol solution and
viewed using an Provis AX 70 Olympus microscope.
Fractionation of Cell Lysates
HeLa cells or ICAP-1–expressing CHO cells were washed in PBS and then
broken on ice in hypotonic buffer (20 mM Tris, 1 mM EDTA, 1 mM EGTA, and
1 mM phenylmethylsulfonyl fluoride [PMSF]) by using a Dounce homoge-
nizer as described previously (Sadoul et al., 1995). After low-speed centrifu-
gation (2500 rpm, 10 min, 4°C, Hera¨us Biofuge) to isolate nuclei, the post-
nuclear supernatant was centrifuged at 30,000  g, 30 min, 4°C to obtain a
crude membrane pellet and cytosol. The membrane pellet was washed once in
high salt buffer (20 mM Tris, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, and 1
M NaCl, pH 7.4) before solubilization with a detergent-containing buffer (20
mM Tris, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 150 mM NaCl, and 1%
Triton X-100, pH 7.4). Solubilized membranes were centrifuged at 100,000 
g, 1 h, 4°C to separate Triton-soluble membrane components from insoluble
material. The remaining pellet was resuspended directly in SDS-sample buffer
for gel electrophoresis. All volumes were kept constant starting with 106
cells/100 l of hypotonic buffer. Fraction purity was tested by Western blot,
by using as a cytoplasmic marker Nm23-H1 and as nuclear marker lamin B.
Cell Proliferation Assay
For proliferation assay, MDCK cells were washed three times in DMEM
before replating 2  104 cells in 3 ml of DMEM supplemented with 4% FCS.
Triplicate wells for each time point were analyzed. The medium was changed
every other day. The total number of viable cells per well was determined by
counting at days 2, 5, 7, and 9 after plating without reaching confluence.
BrdU Incorporation Assay
Cells (1.6  104 cells) were plated on polylysine-, vitronectin-, or fibronectin-
coated coverslips, cultured for 24 h in 1% FCS, and then incubated with 10 M
BrdU (Sigma-Aldrich) for 1 h, washed twice with PBS, and fixed in methanol.
Cells were then treated with 2 N HCl at 37°C for 60 min, washed twice with
0.1 M NaB4O7, and rinsed with PBS. Cell population that entered the S phase
was determined by quantifying the incorporated BrdU by using the mouse
anti-BrdU mAb (Sigma-Aldrich). In parallel, ICAP-1 localization was visual-
ized with the polyclonal antibody. After rinsing, cells were incubated with
appropriate Alexa-conjugated secondary antibodies (Molecular Probes) for 30
min. The cells were mounted in Mowiol solution and viewed using an Provis
AX 70 Olympus microscope for counting or a confocal laser scanning micro-
scope (Zeiss LSM 410).
Reporter Gene Assays
CHO cells were transfected with a pcmyc-driven chloramphenicol acetyl-
transferase (CAT) reporter gene and with the indicated cDNAs, by using the
Exgen 500 reagent (Euromedex). In all cases, the amount of DNA transfected
was kept constant by the addition of the pcDNA3 plasmid (the vector back-
bone for ICAP-1). At the time of harvesting, the cells were placed on ice,
washed twice with ice-cold PBS, and lysed directly on wells with lysis buffer
provided by the manufacturer. CAT expression was measured in cell lysates
48 h after transfection at 405 nm according instructions from Roche Diagnos-
tics.
RESULTS
Dual Localization of ICAP-1 within Cells
To visualize the subcellular localization of ICAP-1, we per-
formed indirect immunostaining on fibroblast NIH 3T3 or
CHO cells overexpressing this protein constitutively (Figure
1A). The use of either monoclonal or polyclonal antibodies
revealed that ICAP-1 was localized in both cytoplasmic and
nuclear compartments. A similar staining was observed in
the lung epithelial cell line H358 (Tet-on) in which ICAP-1
expression was controlled by a tetracycline-dependent pro-
moter. H358 clones with high expression of the rtTA trans-
activator were transfected with pTREhyg plasmid encoding
full-length ICAP-1. On induction with doxycycline, ICAP-1
was observed in the nucleus and the cytoplasm (Figure 1A).
Biochemical fractionations were carried out to assay the dual
cellular locations of the ICAP-1 protein. In all of the men-
tioned cells, endogenous ICAP-1 was difficult to detect ei-
ther by immunofluorescence or Western blot, probably due
to low expression levels. Conversely, HeLa cells express
detectable amounts of endogenous ICAP-1 with a predom-
inant localization in nucleus as visualized by immunostain-
ing (Figure 1B). Because HeLa cells express physiological
levels of endogenous ICAP-1, they were used in a fraction-
ation procedure, separating a cytoplasmic soluble fraction
and a nuclear fraction. These fractions were characterized by
stripping and reprobing the blot by using antibodies di-
rected against marker proteins of different cellular compart-
ments. As expected, Nm23-H1 was found in the cytoplas-
Figure 1. Subcellular localization of ICAP-1.
(A) Different types of cells were plated on
coverslips coated with fibronectin. NIH 3T3
or CHO cells were transiently transfected by
pcDNA3/ICAP-1. Twenty-four hours after
transfection, the cells were fixed, permeabil-
ized, and stained with anti-ICAP-1 polyclonal
antibodies. The H358 cells stably transfected
with pTREhyg/ICAP-1 were induced with 1
g/ml doxycycline during 24 h before fixa-
tion, permeabilization, and immunostaining
with anti-ICAP-1 polyclonal antibodies. Two
photos per cell type are shown to visualize
nuclear and cytoplasmic localization of
ICAP-1. Bar, 10 m. Endogenous ICAP-1 was
visualized in HeLa cells by immunostaining
with anti-ICAP-1 polyclonal antibodies (B)
(bar, 10 m.) and by Western blot (C) by
using the fractionation procedure described
under Materials and Methods. Fractionation
and Western immunoblot analyses of HeLa
cells confirmed the subcellular localization of
ICAP-1 protein in the cytosol and nucleus. Fractions are labeled as follows: C, cytosol; N, nuclear. The various cell fractions were
characterized by reprobing the blots for lamin as a nuclear marker, Nm23-H1 as a cytoplasmic marker and actin as a general marker.
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mic, actin in nuclear and cytoplasmic fractions, and lamin B
was restricted to the nucleus. As shown in Figure 1B, ICAP-1
was detected in both cytoplasmic and nuclear fractions of
HeLa cells consistent with the distribution observed in im-
munofluorescence microscopy experiments.
ICAP-1 Has a Functional Nuclear Localization Signal
To identify a putative NLS in ICAP-1, the complete amino
acid sequence of ICAP-1 was examined using the PSORT
program (Expasy, Swiss Institute of Bioinformatics, Geneva,
Switzerland). A “pat 4” residue pattern similar to the mono-
partite NLS of the SV40 large T antigen was found at posi-
tion 6–9. This sequence usually encompasses three basic
amino acids (K or R) and one histidine. On ICAP-1, this
sequence was KKRH. To determine whether this motif was
a functional NLS and targets ICAP-1 to the nucleus, muta-
tions were introduced, changing the two lysines at position
6–7 to alanines (Figure 2A). After transfection in CHO cells
and immunostaining with anti-ICAP-1 antibodies, exoge-
nous ICAP-1 expression was verified by Western blot (Fig-
ure 2B), and a statistical analysis evaluating for the presence
of ICAP-1 in nucleus was carried out. Figure 2C shows that
ICAP-1 was localized in the nucleus for 60% of transfected
cells. As expected, the AARH mutant showed a diffuse
staining in CHO-transfected cells for 95% of the cells,
demonstrating that the K/A substitution within the NLS
impaired nuclear localization. This indicated that ICAP-1
has a functional NLS in CHO cells. In addition, ICAP-1 was
fused to green fluorescent protein (GFP) to decrease passive
diffusion due to the small molecular weight of ICAP-1.
Figure 2. Mutation in the NLS of full-length ICAP-1 results in the accumulation of the protein in the cytoplasm. (A) Schematic
representation of the different mutants of ICAP-1 used for transfection. CHO cells were transfected with pcDNA3.1 plasmids that express
different ICAP-1 proteins fused or not with GFP, with or without mutations in NLS sequence (NLS corresponds to the change of the two
lysine (KK6–7) of the NLS to alanine and delta 12 corresponds to the deletion of the 12 first amino acids of ICAP-1). (B) Proteins from cells
24 h after transfection were resolved by SDS-PAGE, and the wild-type and mutant ICAP-1 was revealed by Western blot by using ECL
substrate. The NT track corresponds to a lysate of CHO cells transfected with the empty pcDNA3.1. (C) At 24 h posttransfection, the cells
were prepared for immunofluorescence microscopy by using the anti ICAP-1 polyclonal antibodies, and ICAP-1 distribution was examined.
Two patterns were visualized: either nuclear or diffuse. Scoring 100 cells for ICAP-1 protein distribution revealed that ICAP-1 WT resides in
nucleus in 60% of cells, whereas mutation of NLS sequence results in the accumulation of ICAP-1 in the cytoplasm for almost 100% of the
visualized cells. Experiments were independently reproduced at least three times. (D) Western blot analysis performed after cell fractionation
of wild-type CHO and transfected CHO cells overexpressing either wild-type ICAP-1 (WT) or ICAP-1NLS. Note the different distribution
of ICAP-1WT and ICAP-1NLS between the nuclear and the cytoplasmic fraction. Fractions are labeled as follows: C, cytoplasmic fraction;
L, total lysate; M, membrane fraction; N, nuclear fraction.
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Within this construct, an N-terminal ICAP-1 deletion en-
compassing the KKRH sequence as well as AARH mutation
was generated (Figure 2A). The expression of the fusion
proteins was verified by Western blot (Figure 2B). Deletion
of the NLS sequence resulted in a dramatic decrease in the
number of cells displaying nuclear GFP-ICAP-1 (Figure 2C).
To confirm the shift of ICAP-1 distribution induced by NLS
mutation, CHO cells were transiently transfected with
ICAP-1 WT and ICAP-1NLS before performing subcellular
fractionation as described under Materials and Methods.
ICAP-1NLS was predominantly localized in the cytoplas-
mic fraction, whereas wild-type ICAP-1 was equally present
in both cytoplasmic and nuclear fraction (Figure 2D).
1 Integrin Overexpression Shifts ICAP-1 Localization
toward the Cytosol
We then considered whether the nuclear localization of
ICAP-1 could be influenced by binding partners of ICAP-1
such as the cytoplasmic domain of the 1 integrin chain.
When the human 1 chain was coexpressed with ICAP-1 in
CHO cells, ICAP-1 predominantly exhibited a diffuse pat-
tern in 90% of cells, whereas this pattern was only observed
in 40% of the control cells transfected with the ICAP-1–
encoding plasmid alone (Figure 3). The point mutation Y to
S in the NPXY membrane distal (cyto3) domain of the hu-
man 1 integrin abolishes the interaction between ICAP-1
and the 1 cytoplasmic tail (Chang et al., 1997, Bouvard et al.,
2003). To test whether the modification of ICAP-1 localiza-
tion by integrin expression was due to a direct interaction
with the cytoplasmic tail, this mutant was coexpressed with
ICAP-1. Indeed, coexpression of the mutant 1 chain with
ICAP-1 no longer shifted ICAP-1 localization toward the
cytosol. Approximately one-half of the transfected cells ex-
hibited ICAP-1 in nucleus, a distribution similar to that of
the controls (Figure 3). These results suggest that cell adhe-
sion molecules such as 1 integrins may regulate nucleocy-
toplasmic trafficking of ICAP-1, possibly by sequestering the
protein in the cytosol.
Even more clear-cut results were obtained with GD25 cells
(Figure 4). These cells do not express the 1 integrin chain
due to a null mutation in both alleles (Fassler et al., 1995).
Under our experimental conditions, immunofluorescence
microscopy or Western blot analysis did not reveal any
detectable staining for endogenous ICAP-1 in GD25 cells but
ectopically expressed ICAP-1 localized predominantly in the
nucleus. On the other hand, GD25 cells were stably trans-
fected with the human 1A full-length cDNA, called GD25/
1A (Fassler et al., 1995; Retta et al., 1998). In such rescued
cells, ICAP-1 localization was mainly cytosolic (Figure 4, A
and B). Thus, overexpression of 1 integrins in the cells
almost fully abolished the nuclear localization of ICAP-1.
Distinct Contributions of the C- and N-Terminal Halves
of ICAP-1 to Its Cellular Localization
As mentioned above, the N- and C-terminal halves of
ICAP-1 exhibit unique features: The N-terminal moiety en-
compasses the NLS sequence, whereas the C-terminal moi-
ety encompasses the binding site of the 1 integrin tail. To
address the role of each domain regarding to subcellular
localization, we constructed two plasmids expressing either
the N-terminal half or the C-terminal half of ICAP-1, respec-
tively. After transfection of these plasmids into GD25 or
GD25/1A cells, the expressed proteins were visualized by
immunofluorescence with anti-ICAP-1 polyclonal antibod-
ies. As expected, the N-terminal half (1–99 aa), carrying the
NLS sequence, showed a nuclear (70% of cells) or diffuse
(30% of cells) localization in GD25 and GD25/1A cells
(Figure 4, A and C). Conversely, a predominantly cytoplas-
mic distribution was observed in GD25 and GD25/1A cells
tranfected with the C-terminal half (100–200 aa) bearing the
binding domain of integrin and devoid of the NLS sequence
(Figure 4, A and C).
ICAP-1 Overexpression Increases Cell Proliferation
In most cases, the end point of the integrin-induced signal-
ing cascade is the regulation of gene expression programs
that control cell differentiation or proliferation. To determine
whether nuclear ICAP-1 localization affects cell prolifera-
tion, we generated stable MDCK clones overexpressing full-
length ICAP-1 in an inducible manner (tet-off system) and
control cells transfected with the empty vector (MOCK
cells). Multiple independent clones of each cell line were
isolated. Anti-ICAP-1 immunoblot analysis of cell extracts
demonstrated that ICAP-1 protein with the expected size
was expressed in all selected clones upon induction (Figure
5 A). Immunofluorescence studies also showed ICAP-1 ac-
cumulation in the nucleus (Figure 5B). The proliferation
curve of these cell lines, in the presence of 10% serum, was
followed for 5 d. The different clones overexpressing full-
length ICAP-1 consistently exhibited a proliferation increase
of 15% compared with that of control cells (our unpublished
data). This small but reproducible result encouraged us to
measure cell proliferation in low-serum conditions (4%).
Under these conditions and after 7 d of culture, cells had a
proliferation rate 2–3 times higher when ICAP-1 was ex-
pressed (Figure 5C). The next question to be addressed was
to determine whether ICAP-1–induced proliferation was
correlated with its nuclear localization. We generated induc-
ible stable MDCK clones expressing ICAP-1 with the KKRH
Figure 3. 1 Integrin-dependent cytoplasmic translocation of
ICAP-1. CHO cells were cotransfected with two different cDNAs,
pcDNA3.1/ICAP and pECE/human 1 or pcDNA3.1/ICAP-1 and
pECE or pcDNA3.1/ICAP-1 and pECE/human NPXS 1, as indi-
cated in each histogram. The subcellular distribution of the ectopi-
cally expressed proteins was visualized by double immunostaining
by using the anti-human 1 mAb 4B7R and polyclonal anti-ICAP
antibodies. Two distribution patterns were visualized: either nu-
clear or diffuse. Scoring 100 cells for ICAP-1 protein distribution
revealed that human 1 integrin cotransfection resulted in the se-
questration of ICAP-1 in the cytoplasm for 90% of the visualized
cells, whereas the cotransfection with NPXS human 1 integrin
restores the dual cytoplasmic and nuclear distribution. Experiments
were independently reproduced at least three times.
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NLS sequence mutated into AARH (Figure 6). The levels of
ICAP-1NLS expression were comparable with those
achieved with wild-type ICAP-1, as estimated by immuno-
blot (Figure 6B). According to immunofluorescence micros-
copy study, it seemed that mutation in the NLS sequence
redirected ICAP-1 expression from the nucleus to the cyto-
plasmic fraction, thereby preventing nuclear accumulation
of the mutant protein and contrasting with the location of
wild-type ICAP-1 (Figure 6A). Again, we confirmed that the
destruction of this NLS sequence abolishes nuclear import of
ICAP-1 stably expressed in MDCK cells. Proliferation curves
were determined with untransfected MDCK and MOCK-
transfected cells, two MDCK clones overexpressing ICAP-1
(clones 4.9 and 8.9), and three MDCK clones overexpressing
ICAP-1NLS (clones 3.5, 11.3, and 16.2). During the time
course of the experiment, proliferation of MDCK/ICAP-
1NLS cells was comparable with that of control MDCK
cells (Figure 6C), suggesting that the increase in cell prolif-
eration observed upon ICAP-1 overexpression is dependent
on nuclear localization of the ICAP-1 protein.
Next, we address the point whether the loss of ICAP-1
also inhibited cell proliferation. To test this, wild-type
(SV6.5) and ICAP-1–deficient (SV2.1) immortalized osteo-
blasts were used in a BrdU incorporation assay. As expected,
ICAP-1 expression was abolished in null cells (SV2.1 cells)
and restored in SV2.1/ICAP-1 cells upon retroviral infection
(Figure 7A). A homogenous population SV2.1/ICAP-1 cells
was sorted by FACS by using the EGFP fluorescence (Figure
7B). Immunofluorescence studies confirmed a homogenous
ICAP-1 expression in 95% of the SV2.1/ICAP-1 cell pop-
ulation (Figure 7C). In agreement with our previous obser-
vations, we noted a dual localization of ICAP-1 in both
cytoplasm and nucleus. Consistent with the positive effect of
ICAP-1 on cell proliferation, ICAP-1–deficient cells (SV2.1)
had a significant lower proliferation rate assayed by BrdU
incorporation compared either with wild-type osteoblasts
(SV6.5) or with ICAP-1–rescued SV2.1 cells (SV2.1/ICAP-1)
(Figure 7D).
We attempted to establish whether the type of matrix could
regulate ICAP-1–dependent cell proliferation and the potential
shuttling of ICAP-1. BrdU incorporation was carried out in
ICAP-1–deficient cells (SV2.1) and ICAP-1–rescued SV2.1 cells
(SV2.1/ICAP-1) plated on different substrates. SV2/ICAP-1
cells had a higher proliferation rate when cells were spread on
fibronectin compared with polylysine and vitronectin (Figure
7E). In good correlation with these results, a time course of
spreading coupled with a confocal analysis showed that the
nuclear localization of ICAP-1 is linked to the type of matrix
used and is dependent on the stage of spreading of cells:
ICAP-1 displayed a cytoplasmic distribution with a nuclear
exclusion in case of round cells (corresponding to the initial
step of spreading), whereas the distribution of ICAP-1 became
nuclear in case of well spread cells (Figure 7F). On the other
hand, the distribution of ICAP-1 remained cytoplasmic what-
ever the stage of cell spreading onto polylysine. This result
demonstrated that ICAP-1 shuttling is regulated by cell adhe-
sion on a 1 integrin-dependent substrate. Thus, ICAP-1–de-
pendent signaling and subcellular localization of ICAP-1 seem
to be dynamic processes linked to adhesion onto specific ma-
trix proteins.
ICAP-1 Increases Transcriptional Activity from the c-myc
P1 and P2 Promoter
c-myc is a proto-oncogene that has been primarily reported
to stimulate cell proliferation and cell growth (Grandori et
Figure 4. Subcellular localization of ICAP-1 is modulated by 1 integrin expression GD25 or GD25/1 cells were transiently transfected
with pcDNA3.1/ICAP-1, pcDNA3.1/ICAP-1(1-99), or pcDNA3.1/ICAP-1(100-200). (A) Subcellular distribution of the ectopically expressed
proteins was visualized by immunofluorescence by using polyclonal anti-ICAP antibodies. Bar, 10 m. (B and C) Three distribution patterns
were visualized 24 h later as either nuclear, cytoplasmic, or both cytoplasmic and nuclear. Scoring 100 cells for ICAP-1 protein distribution
revealed that cells devoid of 1 integrin sequestered ICAP-1 within nucleus (A and B). The 1–99 fragment bearing the NLS sequence was
located in the nucleus (A and C) independently of the expression of 1 integrins, whereas the 100–200 fragment was sequestered in the
cytoplasm (A and C).
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al., 2000; Pelengaris et al., 2000). One of the ICAP-1 partners,
Nm23-H2 (Fournier et al., 2002), is a putative suppressor of
tumor metastasis in humans. The protein self-assembles into
a hexamer and has dual enzymatic functions, acting as an
NDP kinase and as a transcriptional activation factor. It
binds to a nuclease-hypersensitive element of the c-myc
promoter through which it activates c-myc transcription
(Postel et al., 1993; Berberich and Postel, 1995). Because
ICAP-1 increases cell proliferation and interacts with the
transcriptional activator of the c-myc proto-oncogene Nm23-
H2, we hypothesized that ICAP-1 may be involved in the
regulation of specific genes and more particularly may acti-
vate c-myc transcription. To address the potential relation-
ship between c-myc transcription and ICAP-1–induced cell
proliferation, we performed reporter gene assays by using a
plasmid (pcmycCAT) containing the human c-myc P1 and
P2 promoter driving the bacterial CAT expression. This
plasmid was used in conjunction with either increased
amounts of Nm23-H2 expression vectors, increased amounts
of ICAP-1 expression vectors, or an irrelevant protein ex-
pressing vector. These plasmids were cotransfected into
CHO cells, and the expression of CAT was analyzed 48 h
after transfection by using the CAT enzyme-linked immu-
nosorbent assay kit (Roche Diagnostics). Figure 8A shows
that cotransfection of pcmycCAT with an empty vector or
containing an irrelevant cDNA such as that of -actinin did
not affect the activity of the c-myc promoter and was there-
fore considered as the basal level of CAT expression. In
contrast, a threefold increase in the relative CAT expression
was observed from the wild-type myc promoter in the pres-
ence of Nm23-H2. This activation level is comparable with
the one reported by Postel’s laboratory (1993). Similarly,
cotransfection with the ICAP-1 plasmid resulted in a con-
centration-dependent increase in CAT expression, reaching
Figure 5. Nuclear localization of ICAP-1 in-
creases cell proliferation. (A) MDCK cells sta-
bly transfected with pTREhyg/ICAP-1 were
induced for ICAP-1 expression by removing
doxycycline during 48 h before lysis of the
cells. Total proteins were subjected to gel elec-
trophoresis and then transferred to PVDF
membrane before processing of Western blot
with the anti-ICAP-1 polyclonal antibodies.
The same gel was blotted with anti-actin poly-
clonal antibodies for normalization. (B) Im-
munofluorescence of cells after induction
shows a nuclear localization of ICAP-1. Bar,
10 m. (C) After reducing the percentage of
serum and maintaining cells in 4% serum,
proliferation curves of MDCK cells containing
pTREhyg/ICAP-1 (clone 8.9) or pTRE/hyg
(ct) alone were registered in the absence (in-
duction) or presence of 2 g/ml doxycycline
(dox). The clone 8.9 expressing ICAP-1
shows an increase in cell proliferation after
5 d of induction.
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a threefold induction over the basal level (Figure 8A). The
expression of cyclin D1 known as a c-myc target involved in
cell proliferation also was measured at early and late stage of
spreading on fibronectin in ICAP-1–deficient osteoblasts or
rescued with ICAP-1. The experiments clearly showed a
higher expression of cyclin D1 in the cells rescued with
ICAP-1 in the late stage of cell spreading on fibronectin
(Figure 8B), which nicely correlated with a nuclear localiza-
tion of ICAP-1 (Figure 7). These data support a model in
which ICAP-1 could increase gene expression from c-myc
promoter in a manner comparable with that of Nm23-H2.
The following question was to determine whether ICAP-1
could act synergistically with or independently of Nm23-H2
to activate the c-myc promoter. After cotransfection with
pcDNA3/ICAP-1 and pcDNA3/Nm23-H2, we were able to
detect the threefold induction of CAT expression with
amounts of vectors that did not allow such induction when
they were used separately (see gray histograms in Figure
8C) that favors the view of a synergistic action.
ICAP-1 Control of the c-myc Promoter Requires
Translocation into the Nucleus and Is Independent of Its
Interaction with 1 Integrin
ICAP-1 contains a canonical PTB, a protein module that is
present in a variety of signaling and cytoskeletal proteins. All
known PTB domain proteins contain additional protein–pro-
tein interaction module(s) and are believed to function as adap-
tor proteins in cell signaling (Shc, IRS-1), lineage determination
(numb), and receptor internalization (X11, Fe65, Disabled). Our
previous results have shown that ICAP-1 binds to 1 integrins
and is recruited in lamellipodia (Fournier et al., 2002). Via the
integrin receptors, ICAP-1 might transmit signals from the cell
membrane to the nucleus. On the other hand, some ICAP-1
mutants have been characterized to interact or not with 1
integrins and others to accumulate or not in the nucleus. There-
fore, the question was whether the induction of the reporter
gene controlled by the c-myc promoter is an indirect conse-
quence of integrin activation or due to the nuclear localization
of ICAP-1 and possible association with a transcription com-
plex. As judged by other groups’ reports and according to our
pull-down assays between glutathione S-transferase-1 and
ICAP-1 mutants (our unpublished data), ICAP-1 WT, the 100–
200 fragment and the ICAP-1NLS mutant were all able to
interact with the 1 integrin chain, whereas the 1–99 fragment
and the ICAP-1 I138A mutant showed a defect in the interac-
tion with the 1 integrin cytoplasmic tail. Among the mutants
tested, only the ICAP-1NLS mutant did not accumulate in the
nucleus. As shown in Figure 9, neither the 1–99 fragment, nor
the 100–200 fragment of ICAP-1 was able to operate as activa-
tors of the c-myc promoter. Moreover, the inducibility of the
reporter gene was dependent on the nuclear localization of
ICAP-1 because ICAP-1NLS, devoid of its NLS sequence, was
not able to stimulate the transcriptional activity of the c-myc
promoter. On the other hand, the ICAP-1 I138A mutant that is
compromised in its interaction with the 1 integrin chain could
increase efficiently the transcriptional activity of the c-myc
Figure 6. Cellular distribution of ICAP-1 depends on its NLS sequence and exhibits differential effects on cell proliferation. (A) Subcellular
localization of ICAP-1 was visualized by indirect immunofluorescence analysis with anti-ICAP-1 polyclonal antibodies in MDCK clones
containing pTREhyg (MOCK cells) or pTREhyg/ICAP-1 (ICAP-1 WT) or pTREhyg/ICAP-1NLS (ICAP-1NLS) after induction (dox) or
without induction (dox) with 2 g/ml doxycycline. Bar, 10 m. (B) After 7 d of induction (dox), different clones expressing ICAP-1 WT
(8.9 and 4.9) or ICAP-1NLS (3.5 and 11.3) were lysed and expression of ICAP-1 with expected size was detected by Western blot with
anti-ICAP-1 polyclonal antibodies. The same gel was blotted with anti-actin polyclonal antibodies for normalization. (C) The ratio of cell
proliferation is shown for untransfected MDCK cells, MOCK cells, ICAP-1–overexpressing MDCK cells (clones 4.9 and 8.9), and ICAP-
1NLS–overexpressing MDCK cells (clones 3.5, 11.3, and 16.2) after 7 d of induction.
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promoter. These observations strongly suggest that ICAP-1
integrin binding and its function of transcriptional activation
are two independent events. Together, these data are consistent
with a scenario in which ICAP-1 interacts directly or indirectly
with the c-myc promoter and thereby increases c-myc pro-
moter activity after its translocation into the nucleus.
DISCUSSION
ICAP-1 Shuttles between Nucleus and Cytoplasm
Compartmentalization of signaling molecules is an impor-
tant regulatory mechanism that enables cells to build up an
elaborate a network of signaling pathways. We have previ-
Figure 7. Loss of ICAP-1 decreases cell proliferation in osteoblasts. (A) ICAP-1–deficient osteoblasts (SV2.1) rescued or not with ICAP-1 were lysed with
Laemmli buffer, and total cell lysates were resolved in SDS gel, transferred to a PVDF membrane, and probed with the monoclonal anti-ICAP-1 4D1D6
and anti-actin. (B) ICAP-1–deficient osteoblasts rescued with ICAP-1 (SV2.1/ICAP-1) were sorted by FACS by using EGFP fluorescence. (C) Immuno-
staining of ICAP-1 with polyclonal anti-ICAP-1 antibodies was performed in SV2.1, SV2.1/ICAP-1, SV6.5, and SV6.5/ICAP-1 cells. (D) BrdU incorporation
was carried out in ICAP-1 null osteoblasts (SV2.1), ICAP-1-rescued SV2.1 cells (SV2.1/ICAP-1), wild-type osteoblasts (SV6.5), and SV6.5/ICAP-1. Cells that
have incorporated BrdU were counted under the microscope by using anti-BrdU staining, and the percentage of labeled cells was estimated by
4,6-diamidino-2-phenylindole counterstaining. The results are the average of four experiments allowing us to estimate the SD. (D) BrdU incorporation was
carried out in ICAP-1 null osteoblasts (SV2.1) or in ICAP-1-rescued SV2.1 cells (SV2.1/ICAP-1) plated either on polylysine (PL) or fibronectin (FN) or
vitronectin (VN). Cells that have incorporated BrdU were counted under the microscope by using anti-BrdU staining. The results are the average of three
experiments allowing us to estimate the SD. (E) SV2.1/ICAP-1 cells were allowed to spread onto FN or PL during 15 min (early stage of spreading) or
5 h (late stage of spreading), and then they were fixed, permeabilized, and stained with anti-ICAP-1 polyclonal antibodies. Visualization of a single section
and image capture were done with a confocal microscope.
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ously shown a transitory localization of ICAP-1 at the lead-
ing edge of spreading cells (Fournier et al., 2002). We now
report that endogenous ICAP-1 as well as exogenous ICAP-1
protein can be found both in the nucleus and cytoplasm of a
variety of cultured cells. Two monoclonal antibodies di-
rected against the ICAP-1 N terminus and one polyclonal
antibody consistently showed such a staining pattern. Cell
fractionation experiments provided further evidence for a
nuclear, cytosolic, as well as membrane localization of
ICAP-1 protein. The relative cellular distribution of ICAP-1
between nucleus and cytoplasmic fractions varied among
cell types, but it seems to be regulated by 1 integrin ex-
pression. Control of trafficking between the nuclear and
cytoplasmic compartments is critical for gene expression in
response to a variety of stimuli and therefore provides an
important mechanism whereby cell adhesion molecules may
regulate biological events. In that sense, the observation that
a significant fraction of ICAP-1 protein is localized to the
Figure 8. ICAP-1–mediated activation of the c-myc promoter. (A and C) CHO cells were transiently transfected with the c-myc-CAT P1 and
P2 promoter construct (1 g) along with increasing concentrations of Nm23-H2 expression plasmid (0, 0.5, and 1 g) or ICAP-1 expression
plasmid (0, 0.5, 0.7, and 1 g). In all cases, the amount of DNA transfected was kept constant by the addition of the pcDNA3 plasmid (the
vector backbone for Nm23-H2 or ICAP-1). Extracts were generated 48 h later and assayed for CAT expression. The results are the average
of three experiments allowing us to estimate the SD. (B) SV2.1 and SV2.1/ICAP-1 cells were cultured for 24 h in 1% FCS before replating them
onto fibronectin. After 15 min or 5 h of spreading, cells were washed with PBS and directly lysed onto petri dishes with RIPA buffer. An
amount of 30 g of proteins per lane was subjected to gel electrophoresis and then transferred to PVDF membrane before processing of
Western blot with the anti-cyclin D1 mAb. The same gel was blotted with anti-actin polyclonal antibodies for normalization.
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nucleus of epithelial cells prompted us to search for a puta-
tive nuclear localization signal within the ICAP-1 amino acid
sequence. ICAP-1 protein has a stretch of basic amino acid
residues, bordered by glycines, typical of a nuclear localiza-
tion signal. This NLS sequence was found to be functional
because mutation of KKRH motif into AARH or its deletion
inhibits nuclear accumulation of the protein. According to
our experiments, ICAP-1 nuclear localization seems to be
associated with an increase in cell proliferation, possibly
through the activation of the c-myc promoter. The subcellu-
lar localization of ICAP-1 is probably determined by a bal-
ance of nuclear import and export, and the dynamic equi-
librium between these two processes may determine the
different biological effects of ICAP-1. It is likely that a con-
formational change in ICAP-1 allows the exposure of either
the NLS sequence or the integrin binding domain, although
we cannot completely rule out that ICAP-1 partners that
localize within the nucleus may direct ICAP-1 nuclear im-
port.
Many transcription factors associated proteins either bind
directly to cell adhesion molecules or localize to specialized
adhesion sites. The recruitment of ICAP-1 into nucleus fol-
lows this general scheme and can be influenced by anchor
proteins, such as integrins that could mask the NLS or
sequester the protein. Our data clearly indicate that overex-
pression of 1 integrin strongly reduced nuclear localization
of ICAP-1, suggesting that free and/or unpaired integrins
could modulate ICAP-1 localization by sequestering it out-
side the nucleus. ICAP-1 shuttling is regulated by cell adhe-
sion on a 1 integrin-dependent substrate because nuclear
localization of ICAP-1 is linked to cell adhesion on fibronec-
tin and is dependent on the stage of spreading of the cells.
All these results suggest that integrin-mediated cell adhe-
sion is linked, in some manner, to ICAP-1 nuclear signaling
events and relevant to a given physiological activity of 1
integrins.
How Could ICAP-1 Increase Cell Proliferation?
According to our experiments, ICAP-1 may increase cell
proliferation by acting directly or indirectly on the c-myc
promoter. These data also are supported by studies carried
out with ICAP-1–deficient mice that revealed a defect in cell
proliferation in vivo (Bouvard, Aszodi, Kostka, Block,
Albiges-Rizo, and Fa¨ssler, unpublished data). The question
remains whether this mechanism belongs to a new signaling
pathway or whether is integrated into an already known
pathway. Some results suggest that the integrin 51 coop-
erates with receptor tyrosine kinases to promote extracellu-
lar signal-regulated kinase (ERK) activation necessary for
cell proliferation through two major mechanisms: the Src
family/focal adhesion kinase (FAK) pathway, which is acti-
vated by most of integrins through the cytoplasmic domain
of  subunit, and the Shc/FAK pathway, which is activated
by a subset of integrins through the transmembrane segment
of  subunit (Wary et al., 1996; Pozzi et al., 1998; Barberis et
al., 2000; Hirsch et al., 2002). It seems that the  subunit-
dependent pathway increases the level of ERK activation,
whereas the  subunit-dependent pathway prolongs this
activation and provides crucial signals for ERK nuclear
translocation. This latter event could be controlled by Rac
because the introduction of a constitutively active Rac res-
cues nuclear translocation of ERK, which is suppressed in
cells carrying a mutation in the 1 cytoplasmic domain
(Hirsch et al., 2002). Alternatively, 1 integrins also can
activate c-Jun NH2-terminal kinase signaling through the
FAK/Cas/Rac pathway (Dolfi et al., 1998; Oktay et al., 1999).
Our data indicate that translocation into the nucleus is re-
quired for ICAP-1–dependent transactivation of the c-myc
promoter and stimulation of cell proliferation, thereby
strongly suggesting that the protein may act directly or
synergistically with other nuclear factors such as Nm23-H2.
ICAP-1–induced transcriptional activation of c-myc and
its positive effect on cell proliferation are underlined by
higher expression of the cyclin D1, a classical c-myc tar-
get, in the well spread cells rescued with ICAP-1. This
transcriptional activity correlates with a nuclear localiza-
tion of ICAP-1 and can explain in part the cell prolifera-
tion induced by ICAP-1. However, ICAP-1 also has been
shown to interact with Rac and Cdc42 (Degani et al., 2002)
with a putative Rho GDP dissociation inhibitor activity,
and its association with Nm23-H2 could in turn recruit
Nm23-H1 linked to the Rac exchange factor Tiam1. Thus,
the interference of ICAP-1 through Rac signaling with
other known pathways linking integrins to cell prolifera-
tion cannot be excluded.
Regulation of c-myc Expression by 1 Integrins
A recent report has demonstrated the presence of a 1
integrin-signaling pathway that promotes expression of the
c-myc protein (Benaud and Dickson, 2001), independently of
growth factors, but likely mediated by protein kinase C, Src
kinase family, and ERK mitogen-activated protein kinase
(MAPK). Indeed, the known pathways leading to c-myc
induction, namely, c-Src, ERK1/2 MAPK, and Ras/Akt (Bar-
one and Courtneidge, 1995; Sears et al., 2000; Benaud and
Dickson, 2001) are activated by integrin ligation (Frame and
Brunton, 2002; Howe et al., 2002). Additionally, the activa-
tion of the c-myc promoter via ICAP-1 may correspond to a
new pathway linking directly 1 integrin-mediated cell ad-
hesion to cell proliferation. ICAP-1 is transiently colocalized
with 1 integrins at the leading edge of spreading cells, and
this step also corresponds to c-Src activation. It is tempting
to hypothesize that once the interaction between integrin
and ICAP-1 is broken during the later stages of adhesion, the
protein is sent to the nucleus as a messenger of cell prolif-
eration. This working model could explain how 1 integrins
are up-regulating c-myc gene expression.
Figure 9. Activation of the c-myc promoter requires a functional
NLS of ICAP-1. CHO cells were transiently transfected with the
reporter construct pcmycCAT and the different constructs of
ICAP-1. After 48 h, after lysis, CAT expression was determined
according to the protocol of Roche Diagnostics.
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The profiling of gene expression patterns (10,000 genes)
after c-myc activation in the basal layer of mouse epidermis
has recently been carried out (Frye et al., 2003). The major
classes of up-regulated genes are involved in synthesis and
processing of RNA and proteins that control cell prolifera-
tion and differentiation. Conversely, 40% of the down-
regulated genes code for cell adhesion and cytoskeleton
proteins, in correlation with the inhibition in cell adhesion,
motility, and wound healing. Impaired cell spreading de-
creases hemidesmosome formation and reduces the assem-
bly of the actomyosin cytoskeleton in good correlation with
the decreased expression of the 64 integrin. The authors
proposed that c-myc stimulates exit from the stem cell com-
partment by reducing adhesive interactions with the local
microenvironment or niche and that the failure of hair dif-
ferentiation reflects an inability of keratinocytes to migrate
along the outer root sheath to receive hair inductive stimuli
(Frye et al., 2003). This general reduction of cell adhesiveness
that could result from c-myc activation is consistent with a
general role currently attributed to ICAP-1, namely, the
inhibition of cell adhesion. Additionally, activation of the
c-myc promoter by ICAP-1 may result in a delay or a change
in cell differentiation or polarity due to a hyperproliferative
effect (Liu et al., 2004). It will be crucial to determine the
exact role of ICAP-1 in the nucleus and at the membrane
level after integrin binding to extracellular matrix to under-
stand their respective contributions to cell proliferation. In
conclusion, our results provide novel insights into the cel-
lular roles of ICAP-1 and open a new avenue for a better
understanding of how integrin-mediated cell adhesion is
linked to the control of cell proliferation.
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